Post by icemandios on May 1, 2018 13:29:18 GMT
RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference
MARLBOROUGH, Mass., May 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it will present at the 2018 New York Oncology Investment Conference being held May 8-9, 2018 in New York City. This conference is designed specifically for life science impact investors and provides an intimate setting with a highly screened group of companies and key opinion leaders in the field of oncology.
Logo: mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
Date: Tuesday, May 8, 2018
Time: 12:00 p.m. EDT
Presenter: Dr. Karen Bulock, Vice President of Research
Location: Offices of Wilson Sonsini Goodrich & Rosati in New York City
Dr. Bulock will highlight the Company's sd-rxRNA platform and the ongoing internal and external programs that leverage the self-delivering attributes of its therapeutic compounds in the development of cell-based therapies to treat cancer.
The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com, approximately 1 hour following the presentation.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune cells, such as T-lymphocytes that are isolated from the patient or retrieved from allogeneic immune cell banks, and then expanded and in some cases processed to express tumor-binding receptors. Our approach introduces a new and important step in ex-vivo processing of the immune cells where sd-rxRNA is used to eliminate the expression of immunosuppressive receptors or proteins from the therapeutic immune cells, making them less sensitive to tumor resistance mechanisms and thus improving their ability to destroy the tumor cells. Essentially, we aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack can
MARLBOROUGH, Mass., May 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it will present at the 2018 New York Oncology Investment Conference being held May 8-9, 2018 in New York City. This conference is designed specifically for life science impact investors and provides an intimate setting with a highly screened group of companies and key opinion leaders in the field of oncology.
Logo: mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
Date: Tuesday, May 8, 2018
Time: 12:00 p.m. EDT
Presenter: Dr. Karen Bulock, Vice President of Research
Location: Offices of Wilson Sonsini Goodrich & Rosati in New York City
Dr. Bulock will highlight the Company's sd-rxRNA platform and the ongoing internal and external programs that leverage the self-delivering attributes of its therapeutic compounds in the development of cell-based therapies to treat cancer.
The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com, approximately 1 hour following the presentation.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune cells, such as T-lymphocytes that are isolated from the patient or retrieved from allogeneic immune cell banks, and then expanded and in some cases processed to express tumor-binding receptors. Our approach introduces a new and important step in ex-vivo processing of the immune cells where sd-rxRNA is used to eliminate the expression of immunosuppressive receptors or proteins from the therapeutic immune cells, making them less sensitive to tumor resistance mechanisms and thus improving their ability to destroy the tumor cells. Essentially, we aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack can